Project MK 3475-689 – A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in…

Basic data

Acronym:
MK 3475-689
Title:
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVB Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Duration:
01/04/2018 to 29/02/2024
Abstract / short description:
Pembrolizumab as neoadjuvant therapy and in combinations with standard of care (SoC) radiotherapy (RT) with/without cisplatin as adjuvant therapy is being investigated for participants with newly diagnosed Stage III/IV (IVA/IVB), resectable, locoregionally advanced head and neck squamous cell cancers (LA HNSCC). Its efficacy and safety are being evaluated against SoC treatment in this randomized, open-label, Phase III study.
Keywords:
Pembrolizumab
Hals-Nasen-Ohrenheilkunde
Head &Neck Cancer
Otolaryngology
Oncology

Involved staff

Managers

Faculty of Medicine
University of Tübingen

Local organizational units

Department of Otolaryngology, Head and Neck Surgery; Polyclinic
Hospitals and clinical institutes
Faculty of Medicine

Funders

Haar, Bayern, Germany
Help

will be deleted permanently. This cannot be undone.